Welcome to cobas® Liat®

Review Privacy and Cookie policies

This website uses cookies to deliver content that is tailored to your interests and preferences and to otherwise administer and improve the site.

Privacy Policy

Cookie Policy

Accept and continue

Pushing PCR Further

A historic innovation

Since 1983, Roche has pioneered the advancement of PCR analysis, which is recognized as a gold standard in laboratory diagnostics. The cobas® Liat® PCR System replicates extracted DNA or RNA from patient samples to accurately identify infectious diseases. Using Roche PCR technology, laboratory-quality sensitivity and specificity are achieved across assays, significantly reducing the risk of false negative and false positive results.1

cobas-liat-historic-innovation-image

cobas® Strep A1

Strep A
Sensitivity: 97.7%

Specificity: 93.3%

cobas® Influenza A/B2

Influenza A
Sensitivity: 97.5%

Specificity: 97.9%

Influenza B
Sensitivity: 96.9%

Specificity: 97.9%

cobas® Influenza A/B & RSV3

Influenza A
Sensitivity: 97.5%

Specificity: 97.9%

Influenza B
Sensitivity: 96.9%

Specificity: 97.9%

cobas® Cdiff4

Cdiff
Sensitivity*: 93.5%

Specificity*: 96.4%

Quality without compromise

Patients deserve the best care possible—that means reliable results in a reasonably short amount of time. Current diagnostic options offer a trade-off between speed or accuracy, and since many diseases present similar symptoms at early stages, the need for a reliably accurate point-of-care testing solution is high.

Explore the pros and cons of current diagnostic options

Signs & symptoms

sign-symptopms-mobile-thumb-image

Pro

Quick diagnosis, based on knowledge and experience

Con

Could lead to incorrect antibiotic treatment

On-site rapid antigen test

on-site-rapid-tests-mobile-thumb-image

Pro

Fast results, easy to use

Con

Potentially less accurate, with uncertainty around negative results

Lab cultures

lab-cultures-mobile-thumb-image

Pro

Highly accurate and definitive

Con

Prolongs time for patient diagnosis

Based on Nobel Prize-winning PCR technology, you can be confident that the cobas® Liat® PCR System supports you in delivering the best patient care possible.
Explore the cobas® Liat® System

*Compared to culture and latex agglutination for Strep A typing; CLIA data.
**Compared to viral culture.
Compared to an FDA-cleared laboratory based multiplexed real-time reverse transcription PCR (RT-PCR) test; CLIA data.
††Compared to direct culture.
Compared to direct and enriched culture.
CI=confidence intervals.
cobas® Strep A, cobas® Influenza A/B and cobas® Influenza A/B & RSV are CE-IVD and FDA 510(k) cleared; CLIA waived. cobas® Cdiff is CE-IVD cleared.

References: 1. cobas® Strep A [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2016. 2. cobas® Influenza A/B [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2015. 3. cobas® Influenza A/B & RSV [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2016. 4. cobas® Cdiff [package insert].